Strategic Acquisition

The acquisition is expected to complete in Q3 2026, after which Forte’s shares will be converted to cash at the $77 per share price. The deal is seen as a strategic fit for argenx, aligning with its playbook of compelling biology, strong clinical validation, and broad potential to address unmet patient needs.